Status:
COMPLETED
Pharmacokinetic Interaction Study to Assess the Effect of ASP015K on Tacrolimus in Healthy Volunteers
Lead Sponsor:
Astellas Pharma Inc
Conditions:
Pharmacokinetics of ASP015K
Drug Interactions
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
This study characterizes the pharmacokinetic effects of ASP015K on Tacrolimus in healthy volunteers.
Detailed Description
The subjects will be confined to the unit for 13 days and have a brief follow-up visit to obtain hematology blood samples. Numerous blood and urine samples will be taken to determine the pharmacokinet...
Eligibility Criteria
Inclusion
- If female, the subject is at least 2 years post menopausal or is surgically sterile per documentation provided by a third party medical professional and the subject is not pregnant as documented by a negative serum pregnancy test
- If male, the subject agrees to sexual abstinence and/or to use a highly effective method of birth control during the study period
- Subject is medically healthy, with no clinically significant medical history or abnormalities observed upon physical examination or 12-lead electrocardiogram (ECG)
- Subjects must weigh at least 45 kg and have a body mass index (BMI) of 18-32 kg/m2
Exclusion
- Subject has a history of chronic diarrhea
- Subject has been vaccinated within the last 60 days prior to study drug administration
- The subject has a previous history of any clinically significant neurological, gastro-intestinal, renal, hepatic, pulmonary, metabolic, cardiovascular, psychiatric, endocrine, hematological disorder or disease
- Subject has a positive test for hepatitis C antibody, or positive for hepatitis B surface antigen (HBsAg)
- Subject has a history of the human immunodeficiency virus (HIV) antibody
- The subject has an absolute neutrophil count (ANC) \< 2500 cells/mm3 Subject has had clinically significant illness within 1 month prior to study drug administration
- Subject has a recent history (within the last 6 months) of drug or alcohol abuse or a positive urine screen for alcohol or drugs of abuse/illegal drugs
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT01430065
Start Date
June 1 2009
End Date
June 1 2009
Last Update
September 7 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Pharmacology of Miami
Miami, Florida, United States, 33014